List of Excipients in Branded Drug AVACLYR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Fera Pharmaceuticals LLC	AVACLYR	acyclovir	48102-028	WHITE PETROLATUM

AVACLYR Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

AVACLYR is an acyclovir ophthalmic ointment containing 3% acyclovir in an oleaginous vehicle of mineral oil and white petrolatum. The formulation is preservative-free, avoids aqueous solubility and pH constraints, and is designed for topical treatment of acute herpetic keratitis caused by herpes simplex virus in adults and children two years of age and older.[1] Its main commercial opportunity is a differentiated ophthalmic antiviral product that can replace extemporaneous acyclovir preparations and compete with aqueous antiviral products on formulation tolerability, handling, and clinical familiarity.

What excipients are used in AVACLYR?

AVACLYR contains two inactive ingredients:

Component	Formulation role	Commercial significance
Mineral oil	Liquid hydrocarbon component that softens and lubricates the ointment base	Supports spreadability and ocular surface lubrication
White petrolatum	Semisolid hydrocarbon base and viscosity builder	Provides retention, occlusion, and physical stability

The active ingredient is acyclovir at 3% w/w. The product does not use an aqueous solvent, surfactant, buffer, antimicrobial preservative, or polymeric gelling agent according to the FDA prescribing information.[1]

The excipient selection is commercially important because acyclovir has limited aqueous solubility. An oleaginous base permits incorporation of finely dispersed acyclovir without requiring a high-pH aqueous system, cosolvent, or solubilizing technology. The same approach reduces the need for preservatives that can irritate the ocular surface.

Why does AVACLYR use an oleaginous ophthalmic base?

The mineral oil and white petrolatum system provides four formulation advantages.

First, it creates a water-free dosage form. This avoids the precipitation, pH, buffer capacity, and microbial-control problems associated with aqueous acyclovir products.

Second, the base increases residence time on the corneal and conjunctival surface compared with an aqueous drop. The tradeoff is temporary blurred vision, which is common with ophthalmic ointments and can limit daytime use.

Third, the formulation is inherently compatible with preservative-free positioning. Preservatives such as benzalkonium chloride can damage the ocular surface with repeated exposure, particularly in patients with pre-existing corneal disease or prolonged treatment.[2]

Fourth, mineral oil and white petrolatum are widely used ophthalmic excipients with established manufacturing and compendial precedent. That can reduce regulatory and supply-chain risk compared with a novel lipid, polymer, or nano-enabled carrier.

The principal weakness is that an oleaginous vehicle can produce inconsistent patient handling, variable drug distribution, and visual blurring if particle size, mixing, or rheology is not tightly controlled.

What formulation attributes are protected by AVACLYR?

The commercial differentiation is concentrated in the combination of:

• Acyclovir at ophthalmic strength
• A sterile 3% ointment dosage form
• A mineral oil and white petrolatum vehicle
• Preservative-free delivery
• Topical treatment of herpes simplex keratitis

The formulation does not depend on a complex excipient platform. That limits technological barriers to entry. A generic manufacturer could potentially develop a bioequivalent or pharmaceutically equivalent oleaginous acyclovir ointment if it can reproduce sterility, particle-size distribution, drug uniformity, rheology, tube performance, and ocular tolerability.

The strongest formulation protection would normally come from claims covering the composition, acyclovir particle characteristics, manufacturing process, sterility controls, or use in a defined patient population. Product-specific patent status must be assessed against the current FDA Orange Book and the relevant patent records. The FDA approval record identifies the product and regulatory pathway, but the prescribing information does not establish the full patent estate.[1,3]

What is the FDA regulatory status of AVACLYR?

AVACLYR was approved by the FDA as a prescription ophthalmic antiviral ointment under NDA 214756. The labeled indication is treatment of acute herpetic keratitis caused by herpes simplex virus in adults and children two years of age and older.[1]

Regulatory attribute	AVACLYR
Active ingredient	Acyclovir
Strength	3%
Dosage form	Ophthalmic ointment
Route	Topical ophthalmic
Indication	Acute herpetic keratitis caused by herpes simplex virus
FDA pathway	New Drug Application
Preservative status	Preservative-free formulation
Pediatric labeling	Patients aged two years and older
Treatment regimen	Five times daily until corneal ulceration resolves, followed by three additional days, according to labeling

AVACLYR is not a biologic. Biosimilar competition is therefore irrelevant. The principal future competition would come from generic acyclovir ophthalmic products, alternative ophthalmic antivirals, compounded products, and potentially reformulated antiviral delivery systems.

When does AVACLYR lose exclusivity?

AVACLYR’s loss of exclusivity depends on regulatory exclusivity, listed patents, and the timing of any abbreviated new drug application. The regulatory exclusivity period and patent expiry dates should be separated.

Acyclovir itself is an old active ingredient. Product-level commercial protection therefore depends on the specific ophthalmic formulation, manufacturing technology, labeling, and any applicable patents rather than on new chemical entity protection for acyclovir.

Protection category	Strategic relevance
New chemical entity exclusivity	Unlikely to provide meaningful protection because acyclovir is an established active ingredient
Formulation patents	Potentially relevant if claims cover the ointment composition or drug distribution
Manufacturing patents	Potentially relevant if sterilization, blending, or particle engineering is distinctive
Method-of-use patents	Potentially relevant for treatment populations or dosing regimens
Orphan exclusivity	Not apparent from the labeled indication
Pediatric exclusivity	May apply only if separately granted and listed by FDA
Patent-term adjustment or extension	Must be verified from the issued patent and Orange Book records

A generic entrant would likely target the product through an ANDA and could use Paragraph IV certification if it determines that a listed patent is invalid, unenforceable, or not infringed. A Paragraph IV filing could trigger patent litigation under the Hatch-Waxman framework and potentially impose a 30-month stay on approval, subject to statutory conditions.[4]

How many patents cover AVACLYR?

The relevant number is the count of patents listed for AVACLYR in the current Orange Book, not the number of patents mentioning acyclovir in general. A broad search of acyclovir patents can materially overstate the product’s enforceable protection because most such patents concern systemic formulations, antiviral combinations, or expired technology.

The critical diligence questions are:

1. Which patents are listed against NDA 214756?
2. What claims cover the marketed ointment rather than a broader research formulation?
3. What are the expiration dates, patent-term adjustments, and pediatric extensions?
4. Have any patents been challenged in Paragraph IV litigation?
5. Has the sponsor entered into a settlement or authorized-generic agreement?

No publicly established AVACLYR litigation or settlement should be assumed without confirming the current FDA Orange Book, FDA Paragraph IV notice records, PACER filings, and the sponsor’s disclosures. Patent strength should be scored from claim scope and remaining term, not from the number of patent documents located.

How strong is the AVACLYR patent estate?

The apparent formulation barrier is moderate rather than high.

Strengths

• The product combines a specific active ingredient, strength, dosage form, and ophthalmic indication.
• A sterile ointment can require specialized manufacturing controls.
• Equivalence may be difficult if acyclovir particle size and dispersion materially affect performance.
• Preservative-free ophthalmic manufacturing imposes higher quality requirements than nonsterile topical products.

Weaknesses

• Acyclovir is a mature active ingredient.
• Mineral oil and white petrolatum are established excipients.
• The formulation architecture is relatively simple.
• Compounded and non-branded acyclovir ophthalmic preparations may establish prior art against broad composition claims.
• Generic applicants may be able to design around narrow process or excipient-ratio claims.

The strongest potential claims would cover a narrow, reproducible combination of acyclovir particle attributes, viscosity, drug uniformity, sterile processing, and ocular delivery performance. Claims limited only to “acyclovir in an ophthalmic ointment” could face substantial obviousness and prior-art pressure.

What commercial opportunities exist for AVACLYR’s excipient strategy?

Replacement of compounded ophthalmic acyclovir

A preservative-free, FDA-approved product can compete with pharmacy-compounded acyclovir ointments or suspensions. The value proposition includes standardized strength, sterility assurance, labeled dosing, supply reliability, and reduced pharmacy preparation burden.

This opportunity is strongest in ophthalmology practices, emergency departments, academic medical centers, and hospitals that treat severe ocular herpesvirus infections.

Ocular-surface tolerability positioning

Mineral oil and white petrolatum avoid benzalkonium chloride and other preservatives. The product can be positioned for patients with ocular-surface sensitivity, recurrent disease, contact-lens-related irritation, or concurrent use of multiple topical medicines.

The commercial message must account for ointment-related blurred vision. Preservative-free status is a differentiator, but it does not eliminate adherence problems caused by the dosage form.

Hospital and specialty-pharmacy contracting

Hospitals may value a ready-to-use sterile product when compounded alternatives have uncertain availability or variable preparation practices. Specialty pharmacies and ophthalmology distributors may support targeted rather than mass-market commercialization because herpes simplex keratitis is a focused indication.

Lifecycle reformulation

The current excipient platform creates several possible follow-on products:

Lifecycle product	Potential benefit	Main technical barrier
Lower-viscosity ointment	Improved comfort and less blurred vision	Reduced ocular residence time
Preservative-free gel	Better daytime acceptability	Acyclovir solubilization and stability
Acyclovir lipid suspension	Higher drug loading or improved spreading	Particle control and sedimentation
Unit-dose packaging	Lower contamination risk	Packaging cost and filling yield
Combination antiviral or anti-inflammatory product	Broader treatment utility	Clinical and regulatory complexity
Pediatric unit-dose format	Easier administration and reduced waste	Dose delivery and manufacturing economics

A gel or emulsion would have greater formulation differentiation than the current hydrocarbon ointment, but it would also create new risks involving solubility, preservative control, container compatibility, and ocular irritation.

How does AVACLYR compare with competing ophthalmic antivirals?

Product or approach	Active ingredient	Dosage form	Key excipient or use distinction
AVACLYR	Acyclovir	3% ointment	Preservative-free mineral oil and white petrolatum base
Zirgan	Ganciclovir	0.15% ophthalmic gel	Aqueous gel technology with polymeric viscosity control
Trifluridine ophthalmic solution	Trifluridine	Aqueous solution	Solution dosage form, generally associated with preservative and frequent dosing considerations
Compounded acyclovir	Acyclovir	Variable	Formulation, sterility, and quality depend on compounding process
Oral acyclovir or valacyclovir	Acyclovir or valacyclovir	Systemic dosage forms	Systemic exposure rather than localized ophthalmic delivery

AVACLYR’s clearest differentiation is against aqueous ophthalmic antivirals and compounded formulations. Its main disadvantage is the physical burden of ointment administration. Zirgan may offer better visual acceptability as a gel, while AVACLYR offers a familiar active ingredient and a simple preservative-free base.

What generic entry risks exist for AVACLYR?

Generic entry risk is moderate if the sponsor’s protection relies primarily on a simple ointment composition. The most likely generic development routes are:

1. A pharmaceutically equivalent acyclovir ophthalmic ointment.
2. A composition with the same active ingredient and a different but functionally equivalent oleaginous base.
3. A sterile acyclovir suspension or gel approved through a different regulatory approach.
4. A compounded-product channel that remains available where FDA-approved product access is limited.

The key generic barriers are not the novelty of the excipients. They are sterile manufacturing, drug uniformity, acyclovir particle engineering, tube filling, microbial limits, and product performance after opening.

A generic launch could occur through several scenarios:

Scenario	Commercial effect
No successful Paragraph IV challenge	Branded protection persists until patent or exclusivity expiry
Paragraph IV settlement with delayed entry	Predictable entry date, often with limited near-term erosion
First approved ANDA	Potential 180-day exclusivity for the first qualifying Paragraph IV applicant
Authorized generic	Faster price competition without relying on an independent ANDA launch
Compounding expansion	Localized price and volume pressure, especially during shortages

What manufacturing and supply-chain barriers affect AVACLYR?

The excipients are commercially available, but ophthalmic production remains demanding. Critical controls include:

• Sterile handling and filling
• Homogeneous acyclovir dispersion
• Control of acyclovir particle size
• Ointment viscosity and extrusion force
• Tube and cap compatibility
• Container-closure integrity
• Stability under temperature variation
• Absence of visible particulates and foreign matter
• Consistent delivered dose from the tube

Mineral oil and white petrolatum can create batch-to-batch variability if their grades, hydrocarbon profiles, melting behavior, or supplier specifications differ. A sponsor should qualify multiple suppliers while maintaining tight incoming-material controls. Changes in petrolatum grade can affect viscosity, spreadability, drug dispersion, and patient perception.

The simplicity of the excipient system reduces raw-material complexity, but it does not eliminate process-development work.

What is the revenue exposure and commercial ceiling?

The addressable market is constrained by the incidence of herpes simplex keratitis and the short duration of treatment. AVACLYR is therefore more likely to generate specialty ophthalmology revenue than broad primary-care revenue.

Commercial upside depends on:

• Conversion from compounded acyclovir
• Formulary adoption by ophthalmology practices
• Payer reimbursement relative to generic alternatives
• Distribution through specialty and hospital channels
• Product availability during compounding or supply disruptions
• Ability to establish preservative-free and FDA-approved positioning
• Expansion into additional ocular herpesvirus indications, if clinically and regulatorily supported

Publicly disclosed product-level revenue should not be treated as a reliable proxy for market demand without separating AVACLYR sales from the sponsor’s other products. The commercial ceiling is likely determined more by net price, reimbursement, and prescriber conversion than by excipient innovation alone.

Key Takeaways

• AVACLYR uses a simple preservative-free base of mineral oil and white petrolatum.
• The excipient strategy addresses acyclovir’s poor aqueous solubility and provides prolonged ocular residence.
• The formulation’s strongest commercial advantages are sterility assurance, preservative-free delivery, and replacement of compounded products.
• Its main clinical disadvantage is ointment-related blurred vision and handling burden.
• The patent estate should be evaluated through current Orange Book listings and claim-level analysis; the active ingredient itself is not a meaningful source of exclusivity.
• Generic entry risk is moderate because the excipients are established and the formulation architecture is relatively simple.
• The most attractive lifecycle opportunities are lower-viscosity preservative-free gels, unit-dose packaging, improved particle-engineered suspensions, and targeted hospital or specialty-pharmacy distribution.
• Biosimilar risk does not apply because AVACLYR is a small-molecule drug.

FAQs

Is AVACLYR preservative-free?

Yes. The labeled inactive ingredients are mineral oil and white petrolatum, with no listed antimicrobial preservative.[1]

Can acyclovir be formulated as an ophthalmic gel instead of an ointment?

Yes, but a gel would require a different solubility and stability strategy. The developer would need to control acyclovir precipitation, pH, viscosity, sterility, and ocular tolerability.

Are mineral oil and white petrolatum patentable excipients for AVACLYR?

The excipients themselves are established materials. Any meaningful protection would more likely depend on their specific combination with acyclovir, quantitative ratios, particle attributes, manufacturing process, or clinical use.

What is the biggest barrier to a generic AVACLYR product?

The principal barrier is reproducible sterile manufacture of a uniform acyclovir ointment with acceptable particle size, viscosity, tube performance, and ocular tolerability.

Does AVACLYR compete with oral valacyclovir?

Yes, in selected treatment decisions, but the products deliver antiviral therapy differently. AVACLYR provides localized topical treatment, while oral valacyclovir provides systemic exposure and may be selected when disease severity, recurrence, or extraocular involvement requires systemic therapy.

References

1. U.S. Food and Drug Administration. (2021). AVACLYR (acyclovir ophthalmic ointment) prescribing information.
2. U.S. Food and Drug Administration. (2013). Evaluation of the safety of topical ocular drug products containing preservatives.
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.